Technology | December 06, 2011

Boston Scientific Receives FDA Clearance for New ICDs, CRT-Ds


December 6, 2011 — Boston Scientific Corp. announced U.S. Food and Drug Administration (FDA) approval of its Incepta, Energen and Punctua cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs). The devices are indicated to treat heart failure and sudden cardiac death. 

They offer enhanced therapy options, advanced battery longevity and a DF4 universal connector system in a small, thin platform. The first implant of the Incepta ICD occurred Nov. 29 at the University of Washington Medical Center in Seattle; the procedure was performed by Jeanne E. Poole, M.D., FHRS, FACC, professor of medicine and director, Arrhythmia Service and Electrophysiology Laboratory.

"These devices are a direct response to what patients tell us they want the most — small, thin, long-lasting devices that provide appropriate therapy when necessary," said Poole. "Additionally, these devices are designed to streamline the implant procedure with Boston Scientific's 4-SITE DF4 connector system."

The connector system reduces the volume of the company’s single-chamber ICDs to 30.5cc and CRT-Ds to 32cc, while maintaining a thickness of less than 10mm. The 4-SITE system is also designed to simplify and reduce the time needed for the implant procedure; it accomplishes this by combining three separate lead terminals into one integrated connection and leveraging the new EZ-4 Connector Tool. This allows physicians to reduce the number of steps required during implant.

Each of the new devices also features options to integrate with the Latitude Heart Failure Management weight scale and blood pressure cuff sensors. In this way they can promote appropriate therapy, reduce right ventricular pacing and improve patient management. 

"Including remote monitoring as a standard for patients will assist physicians involved in the management of this very complex disease.  By involving patients in that process, it could also motivate them to become more engaged in their own care," said Leslie A. Saxon, M.D., chief of cardiovascular medicine at University of Southern California. Saxon is also committee chair of the ALTITUDE clinical program sponsored by Boston Scientific.  "In the ALTITUDE Survival study, patients with remote monitoring had a lower mortality rate."

For more information: www.bostonscientific.com


Related Content

News | Implantable Cardioverter Defibrillator (ICD)

Sept. 2, 2024 – Medtronic recently shared long-term results from the global Extravascular Implantable Cardioverter ...

Home September 05, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 12, 2024 — BIOTRONIK, a leader in implantable medical device technology, announced today they will solely ...

Home February 12, 2024
Home
News | Implantable Cardioverter Defibrillator (ICD)

October 23, 2023 — Medtronic plc, a global leader in healthcare technology, has received U.S. Food and Drug ...

Home October 23, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Is the routine implantation of an implantable cardioverter defibrillator (ICD) in myocardial ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 28, 2023 — Upgrade to cardiac resynchronization therapy with a defibrillator (CRT-D) reduces morbidity and ...

Home August 28, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

July 18, 2023 — The U.S. Food and Drug Administration (FDA) has issued a Class I recall on the Medtronic ICDs and CRT-Ds ...

Home July 18, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

March 7, 2023 — Ninety-five percent of athletes with a diagnosed and treated genetic heart disease experienced no ...

Home March 07, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

February 17, 2023 — Medtronic plc has received CE (Conformité Européenne) Mark for the Aurora EV-ICD MRI SureScan ...

Home February 17, 2023
Home
News | Implantable Cardioverter Defibrillator (ICD)

August 29, 2022 — Medtronic plc announced that its investigational EV ICD System – a first-of-its-kind defibrillator ...

Home August 29, 2022
Home
Subscribe Now